High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome.

HER-2 anthracycline breast cancer chemotherapy doxorubicin lapatinib metastasis miR-30 p53 survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 Jun 2021
Historique:
received: 27 05 2021
accepted: 07 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Deregulated miRNA expression has been suggested in several stages of breast cancer pathogenesis. We have studied the miR-30 family, in particular miR-30d, in relation to breast cancer patient survival and treatment outcomes. With tumor specimens from 1238 breast cancer patients, we analyzed the association of miR-30d expression with tumor characteristics with the 5-year occurrence of breast cancer-specific death or distant metastasis (BDDM), and with 10-year breast cancer survival (BCS). We conducted a two-stage drug-screen to investigate the impact of miR-30 family members (miR-30a-30e) on sensitivity to doxorubicin and lapatinib in six breast cancer cell lines HCC1937, HCC1954, MDA-MB-361, MCF7, MDA-MB-436 and CAL-120, using drug sensitivity scores (DSS) to compare the miR-30 family mimics to their specific inhibitors. The study was complemented with Ingenuity Pathway Analysis (IPA) with the METABRIC data. We found that while high miR-30d expression is typical for aggressive tumors, it predicts better metastasis-free (

Identifiants

pubmed: 34200751
pii: cancers13122907
doi: 10.3390/cancers13122907
pmc: PMC8230388
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Helsingin ja Uudenmaan Sairaanhoitopiiri
ID : TYH2017234
Organisme : The Sigrid Juselius Foundation
ID : 2016
Organisme : The Finnish Cancer Society
ID : 70057

Références

J Pathol. 2012 Jul;227(3):306-14
pubmed: 22294324
Nat Rev Mol Cell Biol. 2013 Aug;14(8):475-88
pubmed: 23800994
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
pubmed: 14973191
Oncotarget. 2016 Mar 29;7(13):16462-78
pubmed: 26918943
Oncogene. 2018 Nov;37(48):6195-6211
pubmed: 30002444
Cancer Res. 2010 Apr 15;70(8):3119-27
pubmed: 20354188
Int J Cancer. 2012 May 1;130(9):2044-53
pubmed: 21633953
Nature. 2008 Jan 10;451(7175):147-52
pubmed: 18185580
Oncotarget. 2016 Jan 26;7(4):4009-23
pubmed: 26675258
Nature. 2008 Sep 4;455(7209):64-71
pubmed: 18668037
Nat Commun. 2013;4:1393
pubmed: 23340433
Oncotarget. 2017 Mar 14;8(11):18381-18398
pubmed: 28179588
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Oncogene. 2014 Jun 12;33(24):3119-28
pubmed: 23851509
Hum Mol Genet. 1997 Dec;6(13):2309-15
pubmed: 9361038
Hepatology. 2010 Mar;51(3):846-56
pubmed: 20054866
Breast Cancer Res Treat. 2012 Aug;134(3):1081-93
pubmed: 22476851
Histopathology. 2007 Oct;51(4):491-8
pubmed: 17711446
Sci Rep. 2017 Nov 21;7(1):15945
pubmed: 29162923
Cancer Cell. 2011 Jul 12;20(1):104-18
pubmed: 21741600
Biomed Pharmacother. 2016 Mar;78:335-341
pubmed: 26898459
Am J Pathol. 2000 Nov;157(5):1467-72
pubmed: 11073807
Breast Cancer Res Treat. 2010 Apr;120(2):481-9
pubmed: 20130985
PLoS One. 2011;6(11):e26122
pubmed: 22102859
Nature. 2013 May 16;497(7449):378-82
pubmed: 23644459
Cancer Res. 2012 Jan 1;72(1):154-64
pubmed: 22058146
Oncol Lett. 2018 Mar;15(3):2735-2742
pubmed: 29434998
Nucleic Acids Res. 2015 Sep 3;43(15):7556-65
pubmed: 26227970
Bioinformatics. 2020 Jun 1;36(11):3602-3604
pubmed: 32119072
Clin Cancer Res. 2005 Jul 15;11(14):5098-103
pubmed: 16033823
PLoS One. 2013 Oct 03;8(10):e76247
pubmed: 24098452
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
Am J Pathol. 2013 Sep;183(3):808-19
pubmed: 23831330
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
J Hum Genet. 2017 Jan;62(1):15-24
pubmed: 27439682
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Natl Cancer Inst. 2000 Sep 20;92(18):1529-31
pubmed: 10995809
Sci Rep. 2014 Jun 05;4:5193
pubmed: 24898935
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Br J Cancer. 2001 Mar 2;84(5):704-8
pubmed: 11237395
Braz J Med Biol Res. 2014 Jan;47(1):60-9
pubmed: 24519092
Cell Death Differ. 2019 Nov;26(11):2493
pubmed: 30728458
Genes Chromosomes Cancer. 1999 Oct;26(2):142-50
pubmed: 10469452
Cell Death Differ. 2018 Dec;25(12):2165-2180
pubmed: 29666469
Int J Cancer. 2005 Feb 10;113(4):575-80
pubmed: 15472904
Cancer Res. 2007 Nov 15;67(22):11001-11
pubmed: 18006846
Am J Hum Genet. 2002 Aug;71(2):432-8
pubmed: 12094328
Nat Rev Genet. 2015 Jul;16(7):421-33
pubmed: 26077373
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925

Auteurs

Maral Jamshidi (M)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Rainer Fagerholm (R)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Taru A Muranen (TA)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Sippy Kaur (S)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.
Department of Pathology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Swapnil Potdar (S)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.

Sofia Khan (S)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.
Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Eliisa Netti (E)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

John-Patrick Mpindi (JP)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.

Bhagwan Yadav (B)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.

Johanna I Kiiski (JI)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Kristiina Aittomäki (K)

Department of Clinical Genetics, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.
Department of Clinical Genetics, HUS Diagnostic Center, HUSLAB, 00029 Helsinki, Finland.

Päivi Heikkilä (P)

Department of Pathology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.
Department of Pathology, HUS Diagnostic Center, HUSLAB, 00029 Helsinki, Finland.

Jani Saarela (J)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.

Ralf Bützow (R)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.
Department of Pathology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Carl Blomqvist (C)

Department of Oncology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Heli Nevanlinna (H)

Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, 00029 Helsinki, Finland.

Classifications MeSH